We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Watch Dorothe Nielsen from Novo Nordisk discuss how take-back programs are one piece of a larger puzzle. "I think that companies need to take responsibility for the products all the way through the ...